Formulation: A crystalline solid
Formal Name: (1R,1'R,2R,2'R)-2,2'-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-isoquinolinium, dibenzenesulfonate
Purity: ≥98%
Formula Markup: C53H72N2O12 • 2C6H5O3S
Formula Weight: 1243,5
Shelf life (days): 1460
CAS Number: 96946-42-8
Notes: Cisatracurium is a competitive antagonist of nicotinic acetylcholine receptors (nAChRs) and non-depolarizing muscle relaxant.{43025,43024} It inhibits stimulation of human adult muscle nAChRs by acetylcholine (Item No. 23829) with an IC50 value of 10 nM.{43025} It also inhibits mouse nAChRs with IC50 values of 54 and 115 nM for adult and embryonic receptors, respectively.{43027} Cisatracurium increases apoptosis in HUVEC cells and decreases proliferation of HepG2 and HUVEC cells in vitro in a concentration-dependent manner.{43028,43029} It reduces the magnitude of electrically-evoked twitch tensions in isolated rat extensor digitorum longus and soleus sciatic nerve muscle preparations in a dose-dependent manner.{43024} Cisatracurium blocks electrically-evoked muscle twitches in anesthetized rabbits with an ED95 value of 0.04 mg/kg.{43026} Formulations containing cisatracurium have been used to facilitate intubation prior to surgery and as muscle relaxants.